Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions

Camont, Laurent; Cottart, Charles‐Henry; Rhayem, Yara; Nivet-Antoine, Valérie; Djelidi, Raja; Collin, Fabrice; Beaudeux, Jean-Louis; Bonnefont‐Rousselot, Dominique

doi:10.1016/j.aca.2008.12.003

Cited by 148 publications

(123 citation statements)

References 35 publications

Supporting

Mentioning

114

Contrasting

Order By: Relevance

“…25 The multiple emulsions were first centrifuged at 500×g for 20 min at 23°C. This resulted in a thick cream layer and an aqueous subnatant that was collected using a syringe needle.…”

Section: Quantification Of Resveratrol In the External Aqueous Phasementioning

confidence: 99%

Encapsulation of Resveratrol Using Water-in-Oil-in-Water Double Emulsions

et al. 2010

View full text Add to dashboard Cite

The suitability of water-in-oil-in-water multiple emulsions to encapsulate resveratrol was assessed. Multiple emulsions were prepared by emulsifying a primary emulsion (40 wt.%) in water containing 0.5 wt.% sodium caseinate and 0.1 M NaCl. Four primary emulsions of canola oil (20 wt.%) stabilized by 8 wt.% polyglycerol polyricinoleate were chosen. The dispersed phase of the primary emulsions contained 0.1 M NaCl and either water, 20 wt.% ethanol in water, 2.5 wt.% whey protein isolate (WPI) in water, or 2.5 wt.% WPI and 5 wt.% gelatine in water. Resveratrol was incorporated into these primary emulsions at 0.25 wt.% to give a final 0.02 wt.% resveratrol in the multiple emulsions. Slight increase in particle size with storage at 23°C for up to 2 weeks was observed. Further, less than 10% of the total encapsulated resveratrol is released to the external, continuous, aqueous phase. This work demonstrates the potential of multiple emulsions to encapsulate resveratrol for food applications.

show abstract

“…25 The multiple emulsions were first centrifuged at 500×g for 20 min at 23°C. This resulted in a thick cream layer and an aqueous subnatant that was collected using a syringe needle.…”

Section: Quantification Of Resveratrol In the External Aqueous Phasementioning

confidence: 99%

Encapsulation of Resveratrol Using Water-in-Oil-in-Water Double Emulsions

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Resveratrol is considered a phytoalexin, because it is produced by the plant under stress conditions [5]. Although resveratrol exists in either the cis or trans form, it is the trans isomer that is a more effective anti-oxidant [6], is more bioactive [7], and more stable [7,8]. The presence of resveratrol, along with other polyphenolic compounds in red wine has garnered much attention, especially with regards to their potential role in the protection against CVD [9].…”

Section: Introductionmentioning

confidence: 98%

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Zordoky

Robertson

Dyck

2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

278

217

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide. Despite advancements in diagnosis and treatment of cardiovascular disease, the incidence of cardiovascular disease is still rising. Therefore, new lines of medications are needed to treat the growing population of patients with cardiovascular disease. Although the majority of the existing pharmacotherapies for cardiovascular disease are synthesized molecules, natural compounds, such as resveratrol, are also being tested. Resveratrol is a non-flavonoid polyphenolic compound, which has several biological effects. Preclinical studies have provided convincing evidence that resveratrol has beneficial effects in animal models of hypertension, atherosclerosis, stroke, ischemic heart disease, arrhythmia, chemotherapy-induced cardiotoxicity, diabetic cardiomyopathy, and heart failure. Although not fully delineated, some of the beneficial cardiovascular effects of resveratrol are mediated through activation of silent information regulator 1 (SIRT1), AMP-activated protein kinase (AMPK), and endogenous anti-oxidant enzymes. In addition to these pathways, the anti-inflammatory, anti-platelet, insulin-sensitizing, and lipid-lowering properties of resveratrol contribute to its beneficial cardiovascular effects. Despite the promise of resveratrol as a treatment for numerous cardiovascular diseases, the clinical studies for resveratrol are still limited. In addition, several conflicting results from trials have been reported, which demonstrates the challenges that face the translation of the exciting preclinical findings to humans. Herein, we will review much of the preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular disease and provide information about the physiological and molecular signaling mechanisms involved. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

show abstract

“…et Zucc (1,2). It exists as two geometric isomers: cis-(Z) and trans-(E) (3), and the trans-form can undergo isomerization to the cis-form when exposed to ultraviolet irradiation (4).…”

Section: Introductionmentioning

confidence: 99%

“…Resveratrol (3,5,4' -trihydroxystilbene) is a phytoalexin contained in a variety of plants, such as grapes, peanuts, berries and especially in the dried roots of a traditional Chinese medicine Polygonum cuspidatum Sieb. et Zucc (1,2).…”

Section: Introductionmentioning

confidence: 99%